Therapeutical approach to plasma homocysteine and cardiovascular risk reduction

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 219-224

  Ciaccio, Marcello ^a   Bivona, Giulia ^a   Bellia, Chiara ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

B vitamin; Cardiovascular disease; Folate; Homocysteine; MTHFR

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; REACTIVE OXYGEN METABOLITE;

AMINO ACID METABOLISM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYANOCOBALAMIN DEFICIENCY; ENDOTHELIAL DYSFUNCTION; FATALITY; FOLIC ACID DEFICIENCY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID OXIDATION; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PYRIDOXINE DEFICIENCY; REVIEW; RISK FACTOR; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

EID: 41549121453     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Arnesen E, Refsum H, Bønaa KH, et al. 1995. Serum total homocysteine and coronary heart disease. Int J Epidemiol, 24:704-9.
2. Bellamy MF, McDowell IF, Ramsey MW, et al. 1998. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation, 98:1848-52.
3. Bonaa KH, Niolstad I, Ueland PM, et al. 2006. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med, 354: 1578-88.
4. Bostom AG, Lathrop L. 1997. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int, 52:10-20.
5. Bostom AG, Silbershatz H, Rosenberg IH, et al. 1999. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med, 159:1077-80.
6. Bots ML, Launer LJ, Lindemans J, et al. 1999. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med, 159:38-44.
7. Boushey CJ, Beresford SAA, Omenn GS, et al. 1995. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA, 274:1049-57.
8. Christen WG, Ajani UA, Glynn RJ, et al. 2000. Blood levels of homocysteine and increased risks of cardiovascular disease-causal or casual? Arch Intern Med, 160:422-34.
9. Cook JW, Malinow MR, Moneta GL, et al. 2002. Neointimal hyperplasia in baloon-injured rat carotid arteries: the influence of hyperhomocysteinemia. J Vasc Surg, 35:158-65.
10. Evans RW, Shaten BJ, Hempel JD, et al. 1997. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol, 17:1947-53.
11. Folsom AR, Nieto FJ, McGovern PG, et al. 1998. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation, 98:204-10.
12. Giles WH, Croft JB, Greenlund KJ, et al. 1998. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the third National Health and Nutrition Examination Survey, 1988-1994. Stroke, 29:2473-7.
13. Goyette P, Sumner JS, Milos R, et al. 1994. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet, 7:195-200.
14. Hayden MR, Tyagi SC. 2004. Homocysteme and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroslerapathy: the pleiotropic; effects of folate supplementation. Nutr J, 3:4-27.
15. Hankey GJ, Eikelboom JW. 1999. Homocysteine and vascular disease. Lancet, 354:407-13.
16. Hofmann MA, Lalla E, Lu Y, et al. 2001. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest, 107:675-83.
17. Homocysteine Lowering Trialists' Collaboration. 2002. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr, 82:806-12.
18. Kang SS, Zhou J, Wong PWK, et al. 1989. Intermediate homocysteinemia: a thermolabile variant of methylentethrahydrofolate reductase. Am J Hum Genet, 43:414-21.
19. Kang SS, Wong PWK, Susmano A, et al. 1991. Thermolabile methylene-tetrahydrofolate reductase: an inherited risk factor for coronaru artery disease. Am J Hum Gen, 48:536-45.
20. Kark JD, Selhub J, Bostom A, et al. 1999. Plasma homocysteine and all-cause mortality in diabetes. Lancet, 353:1936-7.
21. Lauricella AM, Quintana I, Castanon M, et al. 2006. Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis, 17:181-6.
22. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. 2003. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol, 41:2105-13.
23. McCully KS. 1969. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol, 56:111-28.
24. Morita H, Kurihara H, Yoshida S, et al. 2001. Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after baloon injury. Circulation, 103: 133-9.
25. Moustapha A, Naso A, Nahlawi M, et al. 1998. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 97:138-41.
26. Nygård O, Nordrehaug JE, Refsum H, et al. 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med, 337:230-6.
27. Perry IJ, Refsum H, Morris RW, et al. 1995. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet, 346:1395-8.
28. Pfanzagl B, Tribl F, Koller E, et al. 2003. Homocysteine strongly enhances metal-catalyzed LDL oxidation in the presence of cystine and cysteine. Atherosclerosis, 168:39-48.
29. Refsum H, Fiskerstrand T, Guttormsen AB, et al. 1997. Assessment of homocysteine status. J Inher Metab Dis, 20:286-94.
30. Refsum H, Ueland PM, Nygard O, et al. 1998. Homocysteine and cardiovascular disease. Ann Rev Med, 49:31-62.
31. Refsum H, Smith AD, Ueland PM, et al. 2004. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem, 50:3-32.
32. Ridker PM, Manson JE, Buring JE, et al. 1999. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA, 281:1817-21.
33. 12 utilization. Bioessays, 12:331-4.
34. Schneider JA, Rees DC, Liu YT, et al. 1998. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet, 62:1258-60.
35. Stampfer MJ, Malinow MR, Willett WC, et al. 1992. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA, 269:877-91.
36. Stehouwer CDA, Gall MA, Hougaard P, et al. 1999. Plasma homocysteine concentration predicts mortality in noninsulin-dependent diabetic patients with and without albuminuria. Kidney Int, 55:308-14.
37. Stehouwer CDA, Weijenberg MP, van den Berg M, et al. 1998. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol, 18:1895-901.
38. Taylor LMJ, Moneta GL, Sexton GJ, et al. 1999. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg, 29:8-19.
39. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. 2006. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med, 354:1567-77.
40. The Homocysteine Studies Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA, 288:2015-22.
41. Toole JF, Malinow MR, Chambless LE. 2004. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stoke, myocardial infarction, and death: the Vitamin Intervention for Stoke Prevention (VISP) randomized controlled trial. JAMA, 291:565-75.
42. Ubbink JB, Fehily AM, Pickering J, et al. 1998. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis, 140:349-56.
43. Ueland PM. 1995. Homocysteine species as components of plasma redox thiol status. Clin Chem, 41:340-2.
44. Ueland PM, Refsum H. 1989. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med, 114:473-501.
45. Ueland PM, Refsum H, Beresford SAA, et al. 2000. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr, 72:324-32.
46. Undas A, Williams EB, Butenas S, et al. 2001. Homocysteine inhibits inactivation of facot Va by Activated Protein C. J Biol Chem, 276:4399-97.
47. Ungvari Z, Sarkadi-Nagy E, Bagi Z, et al. 2000. Simulataneously increased TxA(2) activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. Ather Thromb Vasc Biol, 20:1203-8.
48. Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: evidence on casuality from a meta-analysis. BMJ, 325:1202-9.
49. Wald DS, Morris JK, Law M, et al. 2006. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ, 333:1114-7.
50. Wald NJ, Watt HC, Law MR, et al. 1998. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med, 158:862-7.
51. Weisberg I, Tran P, Christensen B, et al. 1998. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab, 64:169-72.
52. Welch GN, Loscalzo J. 1998. Homocysteine and atherothrombosis. N Engl J Med, 338:1042-50.
53. Wilcken DE, Wilcken B. 1976. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest, 57:1079-82.
54. Woo KS, Chook P, Lolin YI, et al. 1997. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunctionin humans. Circulation, 96:2542-4.